title: Autologous peripheral blood stem cell transplantation (PBSCT) mobilized with G-CSF in AML in first complete remission. Role of intensification therapy in outcome.
abstract: In order to determine if peripheral blood stem cells (PBSC) collected after priming with G-CSF in AML in first complete remission (CR) can be used for autologous transplantation and to evaluate the efficacy of early intensification therapy as in vivo purging, we studied 35 consecutive patients with AML in first CR. After standard induction and consolidation chemotherapy, 24 of them were treated with one (10 patients) or two (14 patients) cycles of high-dose cytarabine plus etoposide prior to PBSC collection. G-CSF was used as the priming agent. Of the 35 patients scheduled for peripheral blood stem cell transplantation (PBSCT), three relapsed before transplantation, and the 32 remaining underwent PBSCT. High-dose therapy consisted of either total body irradiation plus cyclophosphamide or busulphan plus cyclophosphamide. The median number of CD34+ cells infused was 3.24 x 10(6)/kg (range 0.15-14). The median times to reach a PMN count of 0.5 x 10(9)/l and a platelet count of 50 x 10(9)/l were 12 (8-28) and 30 (11-345) days, respectively. There was no transplant-related mortality. Twelve patients relapsed between 2 and 21 months post-PBSCT. With a median follow-up of 28 months, actuarial disease-free survival (DFS) is 52.41 +/- 9% in the intent-to-treat group and 57.4 +/- 9.8% in patients who underwent PBSCT. The probability of DFS is significantly higher for patients who receive early intensification therapy prior to both PBSC collection and PBSCT as compared with patients that do not: 68.8 +/- 10.27% vs 35.5 +/- 12.6%, P = 0.0418. These results indicate the feasibility of PBSCT in AML using G-CSF-mobilized PBSC. The use of intensification treatment as 'purging in vivo' prior both to collection of PBSC and PBSCT significantly reduces the risk of relapse in this group of patients.
authors.affiliation: Department of Hematology, Reina Sofía University Hospital, Cordoba, Spain.
authors.forename: C
authors.initials: C
authors.lastname: Martín
authors.forename: A
authors.initials: A
authors.lastname: Torres
authors.forename: A
authors.initials: A
authors.lastname: León
authors.forename: V
authors.initials: V
authors.lastname: Rubio
authors.forename: M A
authors.initials: MA
authors.lastname: Alvarez
authors.forename: C
authors.initials: C
authors.lastname: Herrera
authors.forename: E
authors.initials: E
authors.lastname: Jean-Paul
authors.forename: M A
authors.initials: MA
authors.lastname: Correa
authors.forename: R
authors.initials: R
authors.lastname: Rojas
authors.forename: R
authors.initials: R
authors.lastname: Campos
authors.forename: J
authors.initials: J
authors.lastname: Serrano
authors.forename: R
authors.initials: R
authors.lastname: Romero
authors.forename: J
authors.initials: J
authors.lastname: Román
authors.forename: J L
authors.initials: JL
authors.lastname: Guzmán
authors.forename: R
authors.initials: R
authors.lastname: Flores
authors.forename: M
authors.initials: M
authors.lastname: Falcón
authors.forename: F
authors.initials: F
authors.lastname: Martínez
authors.forename: P
authors.initials: P
authors.lastname: Gómez
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001781:Blood Component Removal / Q000379:methods; D002648:Child; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage*; D006410:Hematopoiesis; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D015996:Survival Rate; D019172:Transplantation Conditioning / Q000379:methods; D014182:Transplantation, Autologous; D016896:Treatment Outcome
chemical_list: D016179:Granulocyte Colony-Stimulating Factor